References

• 2013Diagnostic and Statistical Manual of Mental Disorders, 5th Edition4,383 cited
• 2014Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial519 cited
• 2010Discovery of the Dual Orexin Receptor Antagonist [(7 R )-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia379 cited
• 2012Orexin receptor antagonism for treatment of insomnia322 cited
• 1990Zolpidem296 cited
• 2003Sleep pathophysiology in posttraumatic stress disorder and idiopathic nightmare sufferers214 cited
• 2013Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men162 cited
• 2012Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial126 cited
• 1996Polysomnographic effects of hypnotic drugs109 cited
• 2011Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study94 cited
• 2012Differential Effects of a Dual Orexin Receptor Antagonist (SB-649868) and Zolpidem on Sleep Initiation and Consolidation, SWS, REM Sleep, and EEG Power Spectra in a Model of Situational Insomnia92 cited
• 2012The Orexin Antagonist SB-649868 Promotes and Maintains Sleep in Men with Primary Insomnia86 cited

Cited by